Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection.
OBJECTIVE
To determine vitreous concentrations of triamcinolone acetonide(TA) following transseptal injection.


METHODS
TA (40 mg/l ml) was administered at varying intervals prior to vitrectomy. Vitreous samples from 18 patients were obtained. TA concentrations were quantified using HPLC-MS.


RESULTS
Vitreous levels of TA were detected in all samples (range 0.64-168.0 ng/ml). The interval from injection to sampling ranged from 0.5-20 days. Tmax was attained at 0.5 days. TA concentrations were negatively correlated with scleral thickness (P = 0.0184) and depot location (P = 0.0230) but not with PVD status (P = 0.9633).


CONCLUSIONS
Significant vitreous concentrations of TA are achieved after a single transseptal injection. Scleral thickness, depot location and time influence vitreous TA levels.
Silva
Paolo S
PS
Sentro Oftalmologico Jose Rizal, University of the Philippines-Philippine General Hospital, Manila, Philippines.
Singh
Ravinder J
RJ
Bakri
Sophie J
SJ
Lising
Ramil S
RS
Santiago
Darby E
DE
Uy
Harvey S
HS
D000328:Adult; D000368:Aged; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D005260:Female; D005938:Glucocorticoids / Q000493:pharmacokinetics*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D009915:Orbit; D014222:Triamcinolone Acetonide / Q000493:pharmacokinetics*; D014822:Vitreous Body / Q000378:metabolism*
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide